trial

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

NCTId NCT02418819
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 103 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2016-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
103 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2015-04
Primary completion
2016-10
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
PF-06412562 3mg BIDPF-06412562 9mg BIDPF-06412562 45mg BID

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

6 total
Arcadia, United StatesGlendale, United StatesGlendale, United StatesBaltimore, United StatesGaithersburg, United StatesRockville, United States

Facts & assertions

4 sourced
Enrollment
103
Phase
PHASE1
Primary Completion Date
2016-10
Status
COMPLETED
relationships
The graph out of here
drug
PF-06412562 3mg BID
drug
PF-06412562 9mg BID
drug
PF-06412562 45mg BID
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication